FASN and non-small cell lung carcinoma: The synergistic effects found in GR models co-treated with FASN inhibitor G28 and EGFR TKIs supports the idea that EGFR palmitoylation mediated by FASN leads to TKI resistance acquisition in EGFRm NSCLC [41].